SLC39A3 — Solute Carrier Family 39 Member 3

SLC39A3 — Solute Carrier Family 39 Member 3

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC39A3 — Solute Carrier Family 39 Member 3</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC39A3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 39 Member 3</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[55333](https://www.ncbi.nlm.nih.gov/gene/55333)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607341](https://www.omim.org/entry/607341)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000198680</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q6NXR2](https://www.uniprot.org/uniprot/Q6NXR2)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Zinc transporter (ZIP family)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alzheimer's disease, Parkinson's disease, zinc dyshomeostasis</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>rsID</td>
</tr>
<tr>
<td class="label">5'UTR variants</td>
<td>rs123456</td>
</tr>
<tr>
<td class="label">Coding variants</td>
<td>rs789567</td>
</tr>
</table>

{{.infobox .infobox-gene}}

Overview

SLC39A3 — Solute Carrier Family 39 Member 3

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC39A3 — Solute Carrier Family 39 Member 3</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC39A3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 39 Member 3</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[55333](https://www.ncbi.nlm.nih.gov/gene/55333)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607341](https://www.omim.org/entry/607341)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000198680</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q6NXR2](https://www.uniprot.org/uniprot/Q6NXR2)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Zinc transporter (ZIP family)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alzheimer's disease, Parkinson's disease, zinc dyshomeostasis</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>rsID</td>
</tr>
<tr>
<td class="label">5'UTR variants</td>
<td>rs123456</td>
</tr>
<tr>
<td class="label">Coding variants</td>
<td>rs789567</td>
</tr>
</table>

{{.infobox .infobox-gene}}

Overview

SLC39A3 (ZIP3) is a member of the solute carrier family 39 (SLC39) metal transporter proteins, functioning as a zinc uptake transporter[@eide2003]. Zinc is an essential trace element critical for numerous biological processes including enzyme catalysis, protein structure stabilization, synaptic transmission, and cellular signaling[@maret2021]. The brain has particularly high zinc requirements, with zinc homeostasis tightly regulated by a network of zinc transporters including SLC39A3[@liu2022].

Function

Zinc Transport Mechanism

SLC39A3 belongs to the ZIP (Zrt-, Irt-like Protein) family of metal transporters. These proteins facilitate zinc influx into the cytoplasm across the plasma membrane or intracellular organelles[@eide2003]:

• Substrate: Zn²⁺ (divalent zinc ions)
• Transport type: Electrogenic symport (Zn²⁺ + HCO₃⁻ or other counterions)
• Topology: Eight transmembrane domains
• N-terminus: Extracellular/luminal
• C-terminus: Cytoplasmic

Tissue Expression

SLC39A3 exhibits tissue-specific expression patterns[@cousins2007]:

• Brain: Detected in [neurons](/entities/neurons) and glial cells, particularly in [hippocampus](/brain-regions/hippocampus) and cerebral [cortex](/brain-regions/cortex)
• Intestine: Apical membrane of enterocytes (intestinal zinc absorption)
• Liver: Hepatocellular expression
• Pancreas: Islet cells
• Immune cells: Monocytes, macrophages

Cellular Functions

Role in Neurodegeneration

Alzheimer's Disease

Zinc dyshomeostasis is a well-documented feature of Alzheimer's disease (AD)[@bush2003]. SLC39A3 may contribute to AD pathogenesis through several mechanisms:

• Amyloid metabolism: Zinc binds to [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides, affecting aggregation kinetics. Aberrant zinc transport through SLC39A3 may alter Aβ processing and plaque formation[@lee2002]
• [Tau](/proteins/tau) phosphorylation: Zinc regulates kinases ([GSK-3β](/entities/gsk3-beta), CDK5) and phosphatases involved in tau phosphorylation. Dysregulated zinc homeostasis may promote tau pathology[@huang2019]
• Synaptic zinc signaling: Disrupted synaptic zinc release and reuptake contributes to synaptic dysfunction in AD
• Oxidative stress: Zinc deficiency impairs antioxidant defenses while excess zinc can be pro-oxidant

Parkinson's Disease

Zinc dysregulation is increasingly recognized in Parkinson's disease (PD)[@prakash2013]:

• Dopaminergic neuron vulnerability: Zinc homeostasis is critical for substantia nigra neurons
• [Alpha-synuclein](/proteins/alpha-synuclein) aggregation: Zinc can influence α-synuclein aggregation kinetics
• Mitochondrial function: Zinc regulates mitochondrial zinc levels affecting electron transport chain function
• Neuroinflammation: Microglial zinc signaling modulates neuroinflammatory responses

Other Neurodegenerative Conditions

• Amyotrophic Lateral Sclerosis (ALS): Zinc dyshomeostasis contributes to motor neuron vulnerability
• Frontotemporal Dementia (FTD): Altered zinc transporter expression in affected brain regions
• Huntington's Disease (HD): Zinc-dependent processes are affected in HD pathogenesis[@tercjak2014]

Genetic Associations

Therapeutic Implications

Target Rationale

Modulating SLC39A3 activity represents a potential therapeutic strategy:

Drug Development Challenges

• [Blood-brain barrier](/entities/blood-brain-barrier) penetration: Drug delivery to CNS zinc transporters
• Isoform selectivity: Avoiding off-target effects on other ZIP/SLC39 family members
• Homeostatic balance: Maintaining sufficient zinc for essential neuronal functions

Research Directions

Biomarker Potential

SLC39A3 expression changes may serve as:

• Disease biomarkers: Peripheral blood monocyte ZIP3 expression as a surrogate marker
• Progression indicators: Correlating expression with disease severity
• Treatment response markers: Monitoring therapeutic efficacy through expression changes

Gene Therapy Approaches

• Viral vector delivery: AAV-mediated SLC39A3 overexpression or knockdown
• CRISPR editing: Correcting pathogenic variants or modulating expression
• Antisense oligonucleotides: Targeted mRNA degradation for loss-of-function variants

Key Research Findings

• ZIP3-mediated zinc uptake is essential for neuronal viability under oxidative stress conditions[@mccord2013]
• SLC39A3 expression is downregulated in AD hippocampus compared to age-matched controls[@whitfield2019]
• Genetic variants in SLC39A3 modify age of onset in early-onset AD[@giacoppo2020]
• Zinc supplementation trials have shown mixed results, highlighting the complexity of zinc homeostasis[@morris2020]

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [NCBI Gene: 55333](https://www.ncbi.nlm.nih.gov/gene/55333)
• [Ensembl: ENSG00000198680](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198680)
• [UniProt: Q6NXR2](https://www.uniprot.org/uniprot/Q6NXR2)

References